ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

New Venture Targets Biobased Butadiene

by Alex Scott
April 15, 2013 | APPEARED IN VOLUME 91, ISSUE 15

Versalis and the industrial biotech firm Genomatica have launched a joint venture to develop technology that converts bio­materials to the rubber raw material butadiene. The firms first disclosed plans for the venture in July 2012. As part of their agreement, Versalis, Italy’s largest chemical maker, will provide $20 million to Genomatica to finance development of the technology. The venture will then license the process across Europe, Asia, and Africa. “We’ve seen lots of different technologies out there. Genomatica was the clear choice,” says Versalis CEO Daniele Ferrari.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment